P

Provention Bio Inc
F:2VB

Watchlist Manager
Provention Bio Inc
F:2VB
Watchlist
Price: 21.6 EUR -0.46% Market Closed
Market Cap: 2B EUR

EV/EBIT
Enterprise Value to EBIT

-16
Current
-14.8
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-16
=
Enterprise Value
1.8B EUR
/
EBIT
-128.2m USD
EBIT Growth EV/EBIT to Growth
US
P
Provention Bio Inc
F:2VB
Average EV/EBIT: 1 874.7
Negative Multiple: -16
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.9
13%
1.4
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
198.6
23%
8.6
CH
Novartis AG
SIX:NOVN
13.4
10%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.7
11%
1
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1.1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A